Recombinant DNA

1. Meaning and scientific basis

Recombinant DNA, often abbreviated as rDNA, is DNA constructed by joining selected DNA segments through laboratory techniques. The segments may come from different organisms, from the same species or from synthetic DNA. When introduced into an appropriate host, the construct can be copied; with suitable regulatory sequences, a gene within it can also be expressed to produce RNA or protein. Recombinant DNA technology therefore links molecular genetics with practical manipulation of biological systems.

The near-universality of the genetic code helps explain why a human gene can direct protein synthesis in a bacterium. However, successful expression is not automatic: the host must recognise the relevant regulatory signals and possess suitable processing machinery. Bacteria generally cannot remove introns from human genes. Consequently, complementary DNA, or cDNA, prepared from mature messenger RNA, is often preferred for bacterial expression of eukaryotic proteins.

Gene cloning, reproductive cloning and genome editing are distinct concepts. Gene cloning produces copies of a DNA sequence, whereas reproductive cloning produces an organism. Genome editing makes targeted changes in genetic material and need not leave foreign DNA in the final organism. Recombinant DNA methods may support genome editing, but the terms are not interchangeable.

• Transgenic organisms carry introduced genetic material, commonly from another species.
• Producing a DNA construct, introducing it into a host and obtaining functional expression are separate achievements.

2. Essential tools: enzymes, vectors and hosts

Restriction endonucleases are molecular tools that cleave DNA at or near particular recognition sequences. Many enzymes used in cloning recognise palindromic sequences: the sequence read in the 5′ to 3′ direction is identical on both complementary strands. EcoRI recognises GAATTC and produces sticky ends. Other enzymes produce blunt ends. Compatible sticky ends can pair through complementary bases, facilitating their subsequent joining.

DNA ligase forms phosphodiester bonds in the sugar-phosphate backbone, sealing DNA fragments together. DNA polymerases synthesise DNA; thermostable polymerases such as Taq enable polymerase chain reaction, or PCR. Reverse transcriptase produces DNA from an RNA template. These enzymes perform different tasks: ligase joins fragments, polymerase extends DNA and reverse transcriptase makes DNA using RNA.

A vector carries the selected DNA into a host. Plasmids are widely used because they can replicate in suitable bacterial cells. Their origin of replication permits replication, selectable markers help identify cells carrying the vector, and cloning sites permit insertion of foreign DNA. Expression vectors additionally contain regulatory elements such as promoters. Bacteriophages, bacterial artificial chromosomes and yeast artificial chromosomes serve other cloning requirements.

Escherichia coli is a common host because it grows rapidly and is genetically well characterised. Yeast, insect and mammalian cells are used when proteins require processing that bacteria cannot adequately perform, particularly complex glycosylation. Host selection therefore depends on the intended product, not merely on growth speed.

• pBR322 is a standard textbook plasmid vector with ampicillin- and tetracycline-resistance genes.
• Selection identifies cells with a selectable property; screening distinguishes desired recombinant clones from other survivors.

3. How recombinant DNA technology works

The process begins by identifying and obtaining the desired sequence. DNA may be isolated from cells, amplified using PCR, synthesised chemically or generated as cDNA. In classical restriction-ligation cloning, the insert and vector are cut to generate compatible ends and joined using DNA ligase. Modern assembly methods can also construct recombinant DNA without following this exact restriction-enzyme workflow.

The construct is introduced into host cells through methods such as chemical transformation, electroporation or vector-mediated delivery. In plants, disarmed Agrobacterium tumefaciens vectors exploit the bacterium’s natural DNA-transfer ability; biolistics delivers DNA-coated particles into cells. Cells carrying the construct are selected, and desired clones are checked using methods such as PCR, restriction analysis and sequencing.

For commercial production, verified producer cells are cultivated under controlled conditions in bioreactors. Temperature, pH, nutrients and oxygen availability influence yield. Downstream processing includes recovery, separation and purification, followed by formulation and quality testing. For medicines, purity, potency, sterility and safety are essential. Making a recombinant organism is therefore only one stage in producing a usable product.

• Gel electrophoresis separates DNA fragments mainly by size; negatively charged DNA moves towards the positive electrode.
• PCR amplifies DNA in vitro, but does not by itself establish a stable recombinant organism.

4. Applications and examination-relevant examples

In medicine, recombinant technology produces human insulin, growth hormone, clotting factors and several therapeutic proteins. Recombinant hepatitis B vaccines contain hepatitis B surface antigen produced in engineered cells, commonly yeast; they do not contain infectious hepatitis B virus. Recombinant vectors also support some gene therapies, although not every recombinant product is a gene therapy.

In agriculture, introduced genes can confer insect resistance, herbicide tolerance or altered nutritional characteristics. Bt cotton carries genes derived from Bacillus thuringiensis that enable production of insecticidal proteins against susceptible pests. It is not resistant to every insect or disease. Golden Rice was engineered to accumulate beta-carotene, a precursor of vitamin A, in the grain endosperm.

Industrial applications include recombinant enzymes used in food processing, detergents and chemical manufacture. Recombinant chymosin is used in cheese-making. Research applications include gene-function studies, reporter systems and recombinant antigens. These examples illustrate that biotechnology products may be purified molecules rather than living genetically modified organisms.

• Recombinant insulin is a protein medicine, not a vaccine.
• A recombinant vaccine need not contain a living genetically modified organism.
• A laboratory application does not establish that a product is commercially approved in India.

5. Biosafety, regulation and public policy

Risk assessment considers the organism, introduced trait, receiving environment and intended use. Possible concerns include allergenicity or toxicity of novel proteins, gene flow to compatible relatives, effects on non-target organisms and evolution of resistance in target pests. These are product-specific questions: neither universal safety nor universal danger can be inferred solely from the use of recombinant DNA.

India’s principal biosafety framework includes the Rules, 1989, under the Environment (Protection) Act, 1986. Institutional Biosafety Committees provide institutional oversight. The Review Committee on Genetic Manipulation operates under the Department of Biotechnology. The Genetic Engineering Appraisal Committee, under the Ministry of Environment, Forest and Climate Change, appraises specified large-scale uses and environmental-release proposals, including experimental field trials.

Recombinant medicines also require relevant drug-regulatory approvals; biosafety oversight does not replace clinical evaluation. Internationally, the Cartagena Protocol on Biosafety addresses living modified organisms, particularly their transboundary movement. A purified recombinant protein is not itself a living modified organism. Biosecurity is related but distinct: it concerns preventing misuse, theft or deliberate harmful application of biological materials and knowledge.

• Confined research, environmental release, food use and medicinal use involve different regulatory considerations.
• Stewardship measures, including appropriate refuge strategies for Bt crops, help delay resistance.

Previous year questions

Practice questions